-
骨肉瘤(osteosarcoma,OS)主要发生在青少年和儿童中,病情发展迅速,病死率高[1]。目前,OS的主要治疗方法包括手术、化疗、免疫疗法和基因疗法等,尽管这些医疗技术对病人生存时间有所改善,但存活率仍然很低,病人预后较差[2]。因此,阐明OS的分子机制,有助于为OS病人的治疗提供新的方法。长链非编码RNA(long non-coding RNA,lncRNA)是一类长度大于200个核苷酸的非编码RNA。近年来,越来越多的研究[3-4]发现,lncRNA在肿瘤的发生和发展中起着极为重要的作用;许多lncRNA在OS中差异表达,并且其表达的失调与OS的发展有关,因为lncRNA可充当致癌因子或肿瘤抑制因子[5-6]。LINC00173是位于12q24.22染色体上的一种lncRNA,在人类多种肿瘤发生和进展中发挥调节作用[7-10]。潘海霞等[11]研究显示,与非肿瘤组织比较,OS组织中LINC00173的表达降低,且与肿瘤分期、远处转移及肿瘤分化密切相关,提示LINC00173参与调节OS的发生发展,因此本实验探讨LINC00173对OS细胞增殖、迁移和侵袭的影响及其调控OS发生和发展的作用机制。现作报道。
-
qPCR检测结果显示,与Mock组比较,pc-LINC00173组LINC00173在MG-63细胞中的表达量明显升高(P < 0.01),而pcDNA组与Mock组差异无统计学意义(P>0.05)(见表 1)。
分组 n LINC00173 Mock组 9 1.00±0.11 pcDNA组 9 0.97±0.10 pc-LINC00173组 9 4.26±0.43** F — 466.361 P — < 0.01 MS组内 — 0.069 q检验:与Mock组比较**P < 0.01 表 1 LINC00173在各组MG-63细胞中表达量比较(x±s)
-
MTT检测结果显示,转染24 h后3组MG-63细胞增殖活力差异无统计学意义(P>0.05);转染48 h和72 h后,pc-LINC00173组细胞增殖活力均低于Mock组和pcDNA组(P < 0.01),pcDNA组与Mock组MG-63细胞增殖活力差异无统计学意义(P>0.05)(见表 2)。
分组 n 吸光度值(λ=450 nm) 24 h 48 h 72 h Mock组 9 0.43±0.04 0.81±0.07 1.14±0.09 pcDNA组 9 0.41±0.04 0.79±0.06 1.10±0.08 pc-LINC00173组 9 0.39±0.04 0.65±0.04**△△ 0.76±0.06**△△ F — 2.25 20.32 6.54 P — >0.05 < 0.01 < 0.01 MS组内 — 0.002 0.003 0.006 q检验:与Mock组**P < 0.01;与pcDNA组比较△△P < 0.01 表 2 转染24、48和72 h后各组MG-63细胞增殖活力比较(x±s)
-
Transwell检测结果显示,pc-LINC00173组与Mock组比较侵袭和迁移细胞数明显减少(P < 0.05),pcDNA组与Mock组比较侵袭和迁移细胞数无明显变化(P>0.05)(见表 3)。
分组 n 侵袭细胞数 迁移细胞数 Mock组 9 100.25±8.12 147.74±10.82 pcDNA组 9 106.33±8.05 150.60±10.28 pc-LINC00173组 9 48.75±3.20* 69.88±6.58* F — 191.67 212.89 P — < 0.01 < 0.01 MS组内 — 46.992 88.682 q检验:与Mock组比较*P < 0.05 表 3 各组侵袭和迁移细胞数比较(x±s)
-
生物信息学在线数据库LncBase Predicted v.2预测结果显示(见图 1),LINC00173与miR-130a-5p之间存在特异性结合位点。双荧光素酶报告基因实验结果显示,与miR-NC组比较,转染miR-130a-5p mimics能够抑制LINC00173-Wt细胞的相对荧光素酶活性(P < 0.01),而2组LINC00173-Mut细胞的相对荧光素酶活性差异无统计学意义(P>0.05)(见表 4)。qPCR检测结果显示,与Mock组和pcDNA组比较,pc-LINC00173组MG-63细胞中miR-130a-5p的表达量均降低(P < 0.01),Mock组和pcDNA组MG-63细胞中miR-130a-5p的表达量差异无统计学意义(P>0.05)(见表 5)。
分组 n LINC00173-Wt LINC00173-Mut miR-NC组 9 1.00±0.09 1.00±0.10 miR-130a-5p组 9 0.34±0.03 0.98±0.09 t — 20.87 0.45 P — < 0.01 >0.05 表 4 各组细胞的相对荧光素酶活性比较(x±s)
分组 n miR-130a-5p Mock组 9 1.00±0.10 pcDNA组 9 1.00±0.09 pc-LINC00173组 9 0.42±0.04**△△ F — 153.685 P — < 0.01 MS组内 — 0.007 q检验:与Mock组比较**P < 0.01;与pcDNA组比较△△P < 0.01 表 5 各组MG-63细胞中miR-130a-5p表达量比较(x±s)
-
与pc-LINC00173组和pc-LINC00173+miR-NC组比较,pc-LINC00173+miR-130a-5p组MG-63细胞中miR-130a-5p的表达明显升高,吸光度值明显升高,侵袭和迁移细胞数明显增多(P < 0.01),pc-LINC00173组和pc-LINC00173+miR-NC以上指标差异无统计学意义(P>0.05)(见表 6)。
分组 n miR-130a-5p 吸光度值 侵袭细胞数 迁移细胞数 pc-LINC00173组 9 1.00±0.10 0.63±0.04 49.37±4.02 67.51±6.21 pc-LINC00173+miR-NC组 9 0.96±0.09 0.64±0.05 48.49±3.95 66.84±6.28 pc-LINC00173+miR-130a-5p组 9 3.44±0.31**△△ 0.79±0.07**△△ 102.43±9.11**△△ 139.84±11.06**△△ F — 477.02 24.10 224.53 237.24 P — < 0.01 < 0.01 < 0.01 < 0.01 MS组内 — 0.038 0.003 38.252 66.775 q检验:与pc-LINC00173组比较**P < 0.01;与pc-LINC00173+miR-NC组比较△△P < 0.01 表 6 各组MG-63细胞中miR-130a-5p的表达、吸光度值、侵袭和迁移细胞数比较(x±s)
lncRNA LINC00173通过调节miR-130a-5p抑制骨肉瘤发生发展的机制研究
Mechanism of lncRNA LINC00173 inhibiting the development of osteosarcoma by regulating miR-130a-5p
-
摘要:
目的探讨长链非编码RNA(lncRNA)LINC00173通过调控miR-130a-5p抑制骨肉瘤发生发展的分子机制。 方法体外培养人骨肉瘤细胞系MG-63,分别将LINC00173过表达载体质粒或空载质粒转染至MG-63细胞,实时荧光定量PCR(qPCR)检测转染效率,采用细胞计数法(CCK-8)和Transwell实验分析MG-63细胞增殖、侵袭和迁移能力,双荧光素酶报告基因实验和qPCR检测LINC00173和miR-130a-5p的靶向调控关系。同时过表达LINC00173和miR-130a-5p,并检测MG-63细胞增殖、侵袭和迁移能力。 结果qPCR检测结果显示,与Mock组比较,pc-LINC00173组LINC00173在MG-63细胞中的表达量明显升高(P < 0.01)。转染48 h和72 h后,pc-LINC00173组细胞增殖活力均低于Mock组和pcDNA组(P < 0.01)。Transwell检测结果显示,pc-LINC00173组与Mock组比较侵袭和迁移细胞数明显减少(P < 0.05)。LINC00173与miR-130a-5p之间存在特异性结合位点,与miR-NC组比较,转染miR-130a-5p mimics能够抑制LINC00173-Wt细胞的相对荧光素酶活性(P < 0.01),与Mock组和pcDNA组比较,pc-LINC00173组MG-63细胞中miR-130a-5p的表达量均降低(P < 0.01)。与pc-LINC00173组和pc-LINC00173+miR-NC组比较,pc-LINC00173+miR-130a-5p组MG-63细胞中miR-130a-5p的表达明显升高,吸光度值明显升高,侵袭和迁移细胞数明显增多(P < 0.01)。 结论LINC00173能够抑制骨肉瘤MG-63细胞增殖、侵袭和迁移,其作用机制可能与靶向抑制miR-130a-5p的表达有关。 -
关键词:
- 骨肉瘤 /
- 长链非编码RNA /
- LINC00173 /
- miR-130a-5p
Abstract:ObjectiveTo investigate the molecular mechanism of long-chain non-coding RNA (lncRNA) LINC00173 through regulating miR-130a-5p to mediate the development of osteosarcoma. MethodsHuman osteosarcoma cell line MG-63 was cultured in vitro, and LINC00173 overexpression vector plasmid or empty plasmid was transfected into MG-63 cells, real-time fluorescence quantitative PCR (qPCR) was used to detect the transfection efficiency. CCK-8 and Transwell assay was used to analyze the proliferation, invasion and migration ability of MG-63 cells, dual luciferase reporter gene experiment and qPCR were used to detect the targeted regulation relationship between LINC00173 and miR-130a-5p. At the same time, LINC00173 and miR-130a-5p were overexpressed, and the proliferation, invasion and migration ability of MG-63 cells were detect. ResultsqPCR results showed that the expression of LINC00173 in MG-63 cells in pc-LINC00173 group was significantly higher than that in Mock group (P < 0.01). After 48 and 72 hours of transfection, the cell proliferation activity of pc-LINC00173 group was lower than that of Mock group and pcDNA group (P < 0.01). Transwell results showed that the number of invading and migrating cells in pc-LINC00173 group was significantly reduced compared with Mock group (P < 0.05). There was a specific binding site between LINC00173 and miR-130a-5p. Compared with the miR-NC group, transfection of miR-130a-5p mimics could inhibit the relative luciferase activity of LINC00173-Wt cells (P < 0.01). Compared with the Mock group and the pcDNA group, the expression of miR-130a-5p in MG-63 cells in pc-LINC0173 group decreased (P < 0.01). Compared with pc-LINC00173 group and pc-LINC00173 + miR-NC group, the expression of miR-130a-5p in MG-63 cells in pc-LINC00173 + miR-130a-5p group was significantly increased, the absorbance value was significantly increased, and the number of invading and migrating cells was significantly increased (P < 0.01). ConclusionsLINC00173 can inhibit the proliferation, invasion and migration of osteosarcoma MG-63 cells, and its mechanism may be related to the targeted inhibition of miR-130a-5p expression. -
Key words:
- osteosarcoma /
- long-chain non-coding RNA /
- LINC00173 /
- miR-130a-5p
-
表 1 LINC00173在各组MG-63细胞中表达量比较(x±s)
分组 n LINC00173 Mock组 9 1.00±0.11 pcDNA组 9 0.97±0.10 pc-LINC00173组 9 4.26±0.43** F — 466.361 P — < 0.01 MS组内 — 0.069 q检验:与Mock组比较**P < 0.01 表 2 转染24、48和72 h后各组MG-63细胞增殖活力比较(x±s)
分组 n 吸光度值(λ=450 nm) 24 h 48 h 72 h Mock组 9 0.43±0.04 0.81±0.07 1.14±0.09 pcDNA组 9 0.41±0.04 0.79±0.06 1.10±0.08 pc-LINC00173组 9 0.39±0.04 0.65±0.04**△△ 0.76±0.06**△△ F — 2.25 20.32 6.54 P — >0.05 < 0.01 < 0.01 MS组内 — 0.002 0.003 0.006 q检验:与Mock组**P < 0.01;与pcDNA组比较△△P < 0.01 表 3 各组侵袭和迁移细胞数比较(x±s)
分组 n 侵袭细胞数 迁移细胞数 Mock组 9 100.25±8.12 147.74±10.82 pcDNA组 9 106.33±8.05 150.60±10.28 pc-LINC00173组 9 48.75±3.20* 69.88±6.58* F — 191.67 212.89 P — < 0.01 < 0.01 MS组内 — 46.992 88.682 q检验:与Mock组比较*P < 0.05 表 4 各组细胞的相对荧光素酶活性比较(x±s)
分组 n LINC00173-Wt LINC00173-Mut miR-NC组 9 1.00±0.09 1.00±0.10 miR-130a-5p组 9 0.34±0.03 0.98±0.09 t — 20.87 0.45 P — < 0.01 >0.05 表 5 各组MG-63细胞中miR-130a-5p表达量比较(x±s)
分组 n miR-130a-5p Mock组 9 1.00±0.10 pcDNA组 9 1.00±0.09 pc-LINC00173组 9 0.42±0.04**△△ F — 153.685 P — < 0.01 MS组内 — 0.007 q检验:与Mock组比较**P < 0.01;与pcDNA组比较△△P < 0.01 表 6 各组MG-63细胞中miR-130a-5p的表达、吸光度值、侵袭和迁移细胞数比较(x±s)
分组 n miR-130a-5p 吸光度值 侵袭细胞数 迁移细胞数 pc-LINC00173组 9 1.00±0.10 0.63±0.04 49.37±4.02 67.51±6.21 pc-LINC00173+miR-NC组 9 0.96±0.09 0.64±0.05 48.49±3.95 66.84±6.28 pc-LINC00173+miR-130a-5p组 9 3.44±0.31**△△ 0.79±0.07**△△ 102.43±9.11**△△ 139.84±11.06**△△ F — 477.02 24.10 224.53 237.24 P — < 0.01 < 0.01 < 0.01 < 0.01 MS组内 — 0.038 0.003 38.252 66.775 q检验:与pc-LINC00173组比较**P < 0.01;与pc-LINC00173+miR-NC组比较△△P < 0.01 -
[1] 康治理, 刘晓伟, 武振方, 等. 基于生物信息学分析的骨肉瘤关键生物标记物的筛选[J]. 蚌埠医学院学报, 2022, 47(3): 386. doi: 10.13898/j.cnki.issn.1000-2200.2022.03.028 [2] WAN Y, QU N, YANG Y, et al. Identification of a 3-gene signature based on differentially expressed invasion genes related to cancer molecular subtypes to predict the prognosis of osteosarcoma patients[J]. Bioengineered, 2021, 12(1): 5916. doi: 10.1080/21655979.2021.1971919 [3] 杨楠, 陈天翔, 刘润坤, 等. 长链非编码RNA LINC00319在肝细胞癌中表达上调并促进肝癌细胞迁移和侵袭[J]. 蚌埠医学院学报, 2022, 47(2): 152. [4] 杨硕, 陈天天, 王文锐, 等. 长链非编码RNA LINC00173在紫杉醇耐药乳腺癌细胞中的作用[J]. 蚌埠医学院学报, 2020, 45(9): 1153. [5] DING L, LIU T, QU Y, et al. lncRNA MELTF-AS1 facilitates osteosarcoma metastasis by modulating MMP14 expression[J]. Mol Ther Nucleic Acids, 2021, 26(1): 787. [6] WANG C, ZHANG T, YANG L, et al. LncRNA BACE1-AS promotes the progression of osteosarcoma through miR-762/SOX7 axis[J]. Mol Biol Rep, 2022, 49(7): 5853. doi: 10.1007/s11033-022-07364-7 [7] YANG W, WANG X, SONG S, et al. Long noncoding RNA ALOX12-AS1 inhibits cervical cancer cells proliferation via targeting miR-3171[J]. Anticancer Drugs, 2022, 33(1): e362. doi: 10.1097/CAD.0000000000001214 [8] MAY-HAU DI, BÁRCENAS-LÓPEZ DA, NÚÑEZ-ENRÍQUEZ JC, et al. Underexpression of LINC00173 in TCF3/PBX1-positive cases is associated with poor prognosis in children with B-cell precursor acute lymphoblastic leukemia[J]. Front Oncol, 2022, 12(1): 887766. [9] ZHANG Y, ZHANG X, ZHU H, et al. Identification of potential prognostic long non-coding RNA biomarkers for predicting recurrence in patients with cervical cancer[J]. Cancer Manag Res, 2020, 12(1): 719. [10] CHEN J, LIU A, WANG Z, et al. LINC00173. v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression[J]. Mol Cancer, 2020, 19(1): 98. doi: 10.1186/s12943-020-01217-2 [11] 潘海霞, 杨兰, 胡洪林, 等. lncRNA NCRNA00173在骨肉瘤组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2017, 24(8): 884. [12] VIMALRAJ S, SUBRAMANIAN R, DHANASEKARAN A. LncRNA MALAT1 promotes tumor angiogenesis by regulating microRNA-150-5p/VEGFA signaling in osteosarcoma: in-vitro and in-vivo analyses[J]. Front Oncol, 2021, 11(1): 742789. [13] ZHAO A, ZHAO Z, LIU W, et al. Carcinoma-associated fibroblasts promote the proliferation and metastasis of osteosarcoma by transferring exosomal LncRNA SNHG17[J]. Am J Transl Res, 2021, 13(9): 10094. [14] ZHANG H, LIU S, TANG L, et al. Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9)[J]. Bioengineered, 2021, 12(1): 162. doi: 10.1080/21655979.2020.1863014 [15] YANG Q, TANG Y, TANG C, et al. Diminished LINC00173 expression induced miR-182-5p accumulation promotes cell proliferation, migration and apoptosis inhibition via AGER/NF-κB pathway in non-small-cell lung cancer[J]. Am J Transl Res, 2019, 11(7): 4248. [16] ZENG F, WANG Q, WANG S, et al. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression[J]. Oncogene, 2020, 39(2): 293. doi: 10.1038/s41388-019-0984-2 [17] YANG F, LEI P, ZENG W, et al. Long noncoding RNA LINC00173 promotes the malignancy of melanoma by promoting the expression of IRS4 through competitive binding to microRNA-493[J]. Cancer Manag Res, 2020, 12(1): 3131. [18] ZHANG J, ZHOU M, ZHAO X, et al. Long noncoding RNA LINC00173 is downregulated in cervical cancer and inhibits cell proliferation and invasion by modulating the miR-182-5p/FBXW7 axis[J]. Pathol Res Pract, 2020, 1(1): 152994. [19] FAN H, YUAN J, LI X, et al. LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression[J]. Biomed Pharmacother, 2020, 125(1): 109987. [20] ZHANG H, SONG J. Knockdown of lncRNA C5orf66-AS1 inhibits osteosarcoma cell proliferation and invasion via miR-149-5p upregulation[J]. Oncol Lett, 2021, 22(5): 757. doi: 10.3892/ol.2021.13018 [21] CHEN J, YAN D, WU W, et al. MicroRNA-130a promotes the metastasis and epithelial-mesenchymal transition of osteosarcoma by targeting PTEN[J]. Oncol Rep, 2016, 35(6): 3285. doi: 10.3892/or.2016.4719